Cross sectional study to investigate the difference in needs between patients and health care providers for systemic therapy of renal cell carcinoma

Not Applicable

• Conditions: Renal cell carcinoma; D046650

• Registration Number: JPRN-jRCT1040220016
• Lead Sponsor: Hiromi Kitano

Brief Summary

This study demonstrated a gap between patients with mRCC and physicians in their expectations and concerns for systemic therapy. Japanese patients with mRCC suffer from a number of adverse events, some of which are not shared with physicians. This study highlights the importance of communicating well with patients in clinical practice to achieve patient-centricity in systemic treatment for mRCC.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-03
• Results First Posted: 2022-10-22
• Study Completion: 2023-06-15
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 83

Inclusion Criteria

- Agreed web questionnaire survey.
- 20 year and older.
- Live in Japan.
- Received or ongoing molecular targeted therapy or immune checkpoint inhibitor (including combination therapy) for renal cell carcinoma.

- Agreed web questionnaire survey.
- Doctors, nurses, or pharmacists who are engaged in systemic therapy of renal cell carcinoma.

Exclusion Criteria

- Have families engaged in pharmatheutical/survey/marketing company or health care.
- Have double cancer.

- Doctors, nurses, or pharmacists who are not engaged in systemic therapy of renal cell carcinoma.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference in preferences of systemic therapy between patients and doctors.

Secondary Outcome Measures

Name	Time	Method
- Difference in preferences of systemic therapy between patients and nurses or pharmacists.<br>- Health care providers who have the most similar preferences of systemic therapy to patients.<br>- The most painful adverse events for patients.<br>- Adverse events which patients are reluctant to tell health care providers.<br>- Difference in recognitions of adverse events between patients and health care providers.<br>- Adverse events which need intervention of nurses or pharmacists.<br>- The most difficult adverse events to manage for health care providers.<br>- Difference in recognitions of adverse events which need intervention of nurses or pharmacists between doctors, nurses, and pharmacists.<br>- Recognition of health care providers for employment status of patients.<br>- Recognition of health care providers for cost of systemic therapy.